New Experimental Approaches to the Adoptive Immunotherapy of Cancer: Cytokines, Gene Therapy, Oncogenes and Transgenic Mice

  • B. A. Fox
Conference paper


Adoptive immunotherapy can be defined as transfer to the tumor bearing host of active immunologic cells with antitumor reactivity that can mediate, directly or indirectly, the regression of established tumors. Within this definition there are at least two distinct approaches to this form of therapy: One is a tumor-specific approach, envisioned as mediated by a classical cytotoxic or T-helper lymphocyte, and the second is a nonspecific approach, potentially mediated by natural killer (NK) cells or a promiscuous cytotoxic T cell.


Major Histocompatibility Complex Class Adoptive Immunotherapy Neor Gene Tumor Bearing Host Nonimmunogenic Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aebersold P, Hyatt C, Johnson S, et al. (1991) Lysis of autologous melanoma cells by tumor infiltrating lymphocytes is associated with clinical response. J Natl Cancer Inst 83: 932PubMedCrossRefGoogle Scholar
  2. 2.
    Asher AL, Mulé JJ, Rosenberg SA (1989) Recombinant human tumor necrosis factor mediates regression of murine sarcoma in vivo via Lyt-2+ cells. Cancer Immunol Immunother 28: 153–156PubMedCrossRefGoogle Scholar
  3. 3.
    Bos JL (1989) Ras oncogenes in human cancer: A review. Cancer Research 49: 4682PubMedGoogle Scholar
  4. 4.
    Cameron RB, McIntosh JK, Rosenberg SA (1988) Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid a-interferon in the treatment of established murine hepatic metastases. Cancer Res 48: 5810PubMedGoogle Scholar
  5. 5.
    Darrow TL, Singluff CL, Siegler HF (1989) The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes: evidence for shared tumor antigens. J Immunol 149: 3329Google Scholar
  6. 6.
    Fox BA, Rosenberg SA (1989) Heterogeneous lymphokine-activated killer cell precursor populations; development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires. Cancer Immunol Immunother 29: 155PubMedCrossRefGoogle Scholar
  7. 7.
    Fox BA, Culver KW, Cornetta K, et al. (1989) Retroviral gene transduction of murine tumor infiltrating lymphocytes: a new approach to study trafficking in vivo. FASEB J 3: (3)3496Google Scholar
  8. 8.
    Fox BA, Spiess PJ, Kasid A, Puri RK, Mule JJ, Weber JS, Rosenberg SA (1990) In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor infiltrating lymphocytes. J Biol Response Mod 9 (5): 499PubMedGoogle Scholar
  9. 9.
    Mulé JJ, Shu S, Schwartz SL, et al. (1984) Successful adoptive immunotherapy of established metastases with LAK cells and recombinant interleukin 2. Science 225: 1487PubMedCrossRefGoogle Scholar
  10. 10.
    Mulé JJ, Yang JC, Lafreniere RL, Shu SY, Rosenberg SA (1987) Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 7:1; 139 (1): 285Google Scholar
  11. 11.
    Pattengale PK, Stewart TA, Leder A, et al. (1989) Am J Pathol 135: 39PubMedGoogle Scholar
  12. 12.
    Rosenberg SA, Spiess PJ, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318PubMedCrossRefGoogle Scholar
  13. 13.
    Rosenberg SA, Lotze MT, Muul LM, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889PubMedCrossRefGoogle Scholar
  14. 14.
    Rosenberg SA, Packard BS, Aebersold PM (1988) Special report: use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676PubMedCrossRefGoogle Scholar
  15. 15.
    Rosenberg SA, Aebersold P, Cornetta K, et al. (1990) Gene transfer into humans — immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570PubMedCrossRefGoogle Scholar
  16. 16.
    Shu S, Rosenberg SA (1985) Adoptive immunotherapy of newly-induced murine sarcomas. Cancer Res 45: 1657PubMedGoogle Scholar
  17. 17.
    Shu S, Chou T, Rosenberg SA (1986) In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J Immunol 136: 3891PubMedGoogle Scholar
  18. 18.
    Shu S, Chou T, Sakai K (1989) Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 143: 740PubMedGoogle Scholar
  19. 19.
    Yang JC, Perry-Lalley D, Rosenberg SA (1990) An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Response Mod 4;9 (2): 149–59PubMedGoogle Scholar
  20. 20.
    Yoshizawa H, Sakai K, Chang AE, Shu S (1991) Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 134: 473PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • B. A. Fox
    • 1
  1. 1.Department of SurgeryUniversity of Michigan Medical CenterAnn ArborUSA

Personalised recommendations